Biohaven Pharmaceutical (BHVN) Buy, Sell or…

Home

Daily Stock Opinions and Ratings

Biohaven Pharmaceutical (BHVN)

14.85

+0.46 (3.20%)

as of Aug 13, 2026, 8:00:00 pm Market Open.

15 watching

Investor Insights

Aug 14, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Biohaven Pharmaceutical, represented by the ticker BHVN-N, is currently advancing several therapeutic candidates in the fields of immunology, oncology, and neuroscience. Despite the promising developments in their pipeline, the company faced significant setbacks over the past year with high-profile failures observed in key clinical trials. These clinical challenges have raised concerns among investors and analysts regarding the viability and market potential of their drug candidates. However, it's essential to recognize the ongoing efforts by the company to navigate these difficulties and refine their strategies for future trials. While uncertainties loom, the scientific groundwork laid by Biohaven may still offer opportunities for recovery and growth in the competitive biopharmaceutical market.

Consensus

Cautious

Valuation

Fair Value

Similar

ACAD,ACAD

COMMENT

They have several drugs under trial in immunology, oncology and neuroscience. Are making good progress but last year they had some high-profile failures in key clinical trials.

DON'T BUY

Shares sold off last week after the FDA refused to review one of their drugs. Could be a buying opportunity, but the company is losing money.

BUY

The new Biohaven began trading last October after Pfizer bought the old one only for its migraine drug. The new Biohaven is far more speculative because there are many drugs in the pipeline in early stages. They held an R&D day this week and shares soared. He has faith in their new drugs.

BUY

A favourite of his. It plunged from $139 to $121 today. Whoa. Yesterday morning, they reported a solid quarter, and partnered with Pfizer to sell their big migraine pill overseas. But BHVN pre-announced strong results in early October so the good news is baked into the stock. The Pfizer news may be seen as a negative, because many investors expected BHVN to be a takeover candidate.

COMMENT

The caller bought at $33 It reports tomorrow afternoon. He likes it alot and uses their migraine money. Sell an amount equal to your cost based on $33/shares, then let it run. This way, you can't lose money.

BUY

Their super pill helped him control his migraine, so he's a fan of this stock.

BUY

Their drugs treated his migraine beautifully. The stock was downgraded yesterday, but he loves it.

COMMENT

They sell a super migraine pill he uses. It popped a year from around $25 to $100 in November, but since then it's pulled back to $72 today. It's a victim of the current rotation out of tech into cyclicals. That migraine pill is a steady seller and Biohaven also has a Parkinson's treatment in the pipeline as well as one for ALS. It could be worth buying into weakness.

BUY

Renown for their new migraine drug. Shares have tripled since April. He see more upside with their migraine pill (which he himself has taken and it's effective). Also consider their Alzheimer's drug which is being tested now.

Showing 1 to 9 of 9 entries

Most Recent Experts

Stan Wong

Private Wealth Management, ScotiaMcleod

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Chris Blumas

at Raymond James Investment Counsel Ltd.

Shannon Saccocia, CIO, Boston Private

Boston Private

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Biohaven Pharmaceutical (BHVN) Frequently Asked Questions

What is Biohaven Pharmaceutical stock symbol?

Biohaven Pharmaceutical is a American stock, trading under the symbol BHVN (previously BHVN-N on Stockchase) on the New York Stock Exchange (BHVN). It is usually referred to as NYSE:BHVN or BHVN

Is Biohaven Pharmaceutical a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on BHVN (previously BHVN-N on Stockchase) on Stockchase. Read the latest expert commentary for Biohaven Pharmaceutical .

Is Biohaven Pharmaceutical a good investment or a top pick?

Biohaven Pharmaceutical was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Biohaven Pharmaceutical .

Why is Biohaven Pharmaceutical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Biohaven Pharmaceutical .

Is Biohaven Pharmaceutical worth watching?

Biohaven Pharmaceutical is followed by 15 investors on Stockchase and is a trending stock that is worth watching.

What is Biohaven Pharmaceutical stock price?

On 2026-08-13, Biohaven Pharmaceutical (BHVN) stock closed at a price of $14.85.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Biohaven Pharmaceutical (BHVN)